Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
TYK Medicines, Inc. Class H ( (HK:2410) ) has provided an update.
TYK Medicines, Inc announced the resignation of Dr. Jiang Mingyu from his roles as vice-president, Board secretary, and joint company secretary, effective June 13, 2025, to focus on other business engagements. Dr. Jiang will transition to a non-executive director role, while Ms. Wong Wing Yee will continue as the sole company secretary. This change is part of the company’s strategic management restructuring, potentially impacting its governance and operational dynamics.
The most recent analyst rating on (HK:2410) stock is a Buy with a HK$31.60 price target. To see the full list of analyst forecasts on TYK Medicines, Inc. Class H stock, see the HK:2410 Stock Forecast page.
More about TYK Medicines, Inc. Class H
TYK Medicines, Inc is a joint stock company incorporated in the People’s Republic of China, operating in the pharmaceutical industry. The company focuses on developing and providing innovative medical solutions, with a market presence in Hong Kong as indicated by its listing on the Hong Kong Stock Exchange.
Average Trading Volume: 2,201,614
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$8.04B
See more insights into 2410 stock on TipRanks’ Stock Analysis page.